Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants

PURPOSE: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy. EXPERIMENTAL DESIGN: 289 patients with gene expression profiling (GEP70)-defined low-risk multiple myeloma (LRMM) were randomized between a standard arm (TT4-S) and a light arm (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Jethava, Yogesh S, Mitchell, Alan, Epstein, Joshua, Zangari, Maurizio, Yaccoby, Shmuel, Tian, Erming, Waheed, Sarah, Khan, Rashid, Papanikolaou, Xenofon, Grazziutti, Monica, Cottler-Fox, Michele, Petty, Nathan, Steward, Douglas, Panozzo, Susan, Bailey, Clyde, Hoering, Antje, Crowley, John, Sawyer, Jeffrey, Morgan, Gareth, Barlogie, Bart, van Rhee, Frits
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6080620/
https://ncbi.nlm.nih.gov/pubmed/27810902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2620
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados